LINK Medical, the Northern European CRO has raised capital to fund further growth

May 2, 2022, LINK Medical and Serendipity Partners announce a new partnership.

Serendipity Partners (Serendipity) has been invited as part owner of LINK Medical. Serendipity now owns 49% of the shares, however Dr. Ola Gudmundsen will stills hold the majority of the shares. The transaction is mainly structured as a share issue, where Serendipity provides growth capital to LINK Medical.

LINK Medical and Serendipity share the vision of building a strong Northern European CRO.

For almost 27 years, LINK Medical has grown steadfastly, one step after the other. The funds generated have been invested into growing the company, making LINK Medical today one of the largest independent CROs in the Nordics.

To enable further growth and provide new competencies to the company, Ola Gudmundsen has decided to invite Serendipity as co-owners and long-term investors in LINK Medical.

“I have known the founders of Serendipity Partners for many years. As an investment fund specializing in life science, and with a base in Oslo, Serendipity Partners is the best partner for us. More than just capital, they can add knowledge and competence, as Serendipity is run by medical doctors, pharmacists, and others with an extensive experience in pharma or biotech industries. For a long time, I have worked with Serendipity to make sure that this partnership is a good fit for us, and we are all very enthusiastic to have found a common platform for cooperation.” says Dr. Ola Gudmundsen.

Michael Bodd from Serendipity Partners will be the chairman of the board in LINK Medical. His colleague Christopher Tangen will also join the board, alongside Ola Gudmundsen and Renee Amundsen.

About LINK Medical

LINK Medical is a full-service contract research organization (CRO) providing product development services for the pharmaceutical and medical device industries across Northern Europe. LINK Medical offers a well-integrated local presence in the Nordic region, Germany and UK. Reaching from early phase development to post-marketing, the company has around 200 employees providing expert guidance across every aspect of a project – all from one source. LINK Medical’s promise is to improve and accelerate product development through transformative methods, active communication, and optimal solutions. As a strategic partner, LINK Medical provides expert competence and technology to enable evidence-based decision-making that supports the delivery of superior clinical outcomes.

For more information contact
Ola Gudmundsen, CEO
Ola.Gudmundsen@LINKMedical.eu
+47 924 62 200

Editorial Enquiries:
Claudia Wennberg
Marketing and Brand Manager
Claudia.Wennberg@LINKMedical.eu
+46 708 244 398

About Serendipity Partners

Serendipity Partners is the manager of two healthcare funds, which invest in healthcare companies that provide benefits to patients and society. The main healthcare segments that the fund invests in are pharmaceuticals, diagnostics, providers of healthcare services and medical technology. The fund has a Nordic focus and an established network of experienced leaders with experience from the healthcare sector. Serendipity Partners has 1.8 billion NOK under management.

For more information contact
Michael Bodd (the new chairman)
mbodd@serpar.no
+47 98670250